Pluristem Participates in Radiation Injury Treatment

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Pluristem Participates in Radiation Injury Treatment Network Conference Co-sponsored by National Institutes of Health’s NIAID

HAIFA, Israel, July 20, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc . (Nasdaq: PSTI ) (TASE: PLTR ), a leading developer of placenta-based cell therapy products, today announced its participation in the Radiation Injury Treatment Network’s meeting titled, “Medical Management of Radiation Casualties: Where Research and Usage Meet”. The meeting, which took place on July 18-19, 2016, was organized jointly by the Radiation Injury Treatment Network and the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID).

Racheli Ofir, Ph.D., Pluristem’s Vice President of Research & Intellectual Property, shared her expertise in studying the treatment of Acute Radiation Syndrome (ARS) in a variety of animal models.

“We are pleased to have been invited to participate in this important event. It highlights our continued collaboration with the NIH’s NIAID to develop PLX-R18 as a treatment for the hematologic component of ARS,” said Zami Aberman, Chairman and CEO of Pluristem Therapeutics.

Pluristem’s scientists, together with researchers at several academic institutions, Hadassah Medical Center and at the NIAID, have studied the Company’s PLX-R18 cells as a potential treatment for the hematologic subsyndrome of ARS. They have also used animal and in vitro models to delineate the unique mechanism of action of PLX-R18 in this indication. Data have demonstrated that PLX-R18 cells release a spectrum of therapeutic proteins in response to inflammatory cytokines secreted by animals with acutely damaged bone marrow caused by exposure to high levels of radiation. The therapeutic proteins from PLX-R18 cells work to stimulate recovery of hematopoietic function, addressing production of all three blood cell lineages.

As previously announced, the U.S. FDA recently cleared Pluristem’s Phase I trial of PLX-R18 in the treatment of insufficient hematopoietic recovery following hematopoietic cell transplantation.

PLX-R18 Mechanism of Action in Hematologic Indications

PLX-R18 cells sense the inflammatory cytokines that are secreted by the body following hematopoietic failure, and respond by releasing a spectrum of therapeutic proteins such as G-CSF (induces HSC mobilization), MCP-1 (induces chemotaxis of monocytes and basophils) and IL-6 (assists in renewal and differentiation of hematopoietic cells). Preclinical studies showed that the proteins released by PLX-R18 attained peak levels before accelerated cellularity and progenitor cell recovery were detected within the bone marrow. Treatment with PLX-R18 was associated with 98% survival versus 30% survival in a control group that was treated with a placebo.  Intramuscular injection of PLX-R18 into naïve mice induces only a negligible response, in contrast to the reaction in irradiated mice, suggesting detection of ARS-related signals by PLX-R18.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapy products. The Company has reported robust clinical trial data in multiple indications for its patented PLX (PLacental eXpanded) cells. The cells release a range of therapeutic proteins in response to inflammation, ischemia, hematological disorders, and radiation damage. PLX cell products are grown using the Company's proprietary three-dimensional expansion technology. They are off-the-shelf, requiring no tissue matching prior to administration.

Pluristem has a strong intellectual property position; Company-owned and operated, GMP-certified manufacturing and research facilities; strategic relationships with major research institutions; and a seasoned management team.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, forward-looking statements are used in this press release when we discuss PLX-R18 cells as a potential treatment for the hematologic subsyndrome of ARS, prior models and data relating to the Company’s PLX-R18 cells and the Company’s Phase I trial of PLX-R18 in the treatment of insufficient hematopoietic recovery following hematopoietic cell transplantation. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

Contact: Pluristem Therapeutics Inc. Karine Kleinhaus, MD, MPH Divisional VP, North America 1-914-512-4109 karinek@pluristem.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Older Adults Embrace Cosmetic Dentistry for Confidence

Updated Category News Views 161

Why the Shift to Cosmetic Dentistry Later in Life? Aging doesn't just wrinkle your skin; it affects your smile too. Dr. Joseph T. Sumrall and Dr. Gran Sumrall, the dental gurus of Warner Robins, Georgia, are laying out why more adults are jumping on the cosmetic dentistry bandwagon as they age. Spoiler: It ain't about getting a movie-star grin but something much deeper....

Continue Reading
Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 127

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading
Kinross Gold Fraud Lawsuit: What Shareholders Need to Know

Updated Category News Views 58

Kinross Gold's Legal Quagmire There's a fresh storm brewing for Kinross Gold Corporation (NYSE: KGC), and it ain't the kind investors enjoy riding. You see, the company is up to its neck in a class action lawsuit, courtesy of Schall, Brown & Schwartz LLP—a big-name shareholder rights litigation outfit. The gripe? Alleged securities fraud, violating §§10(b) and 20(a)...

Continue Reading
Choate's Expands to New Mid-South Markets

Updated Category News Views 118

Family Traditions Drive Choate's Growth Back in the day, you might've thought the family-run businesses were a dying breed, right? Not in the case of Choate's Air Conditioning, Heating, Plumbing & Electrical. These folks aren't just holding the fort; they're storming new territories across the Mid-South like they've got something to prove—or maybe just something to...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 147

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading
SiteOne Joins S&P SmallCap 600 Amid KKR's Integer Buyout

Updated Category News Views 89

Changes on the SmallCap Horizon Starting off, SiteOne Landscape Supply (NYSE: SITE) is hopping onto the S&P SmallCap 600 bandwagon. This shift activates just as the market revs up on November 19, 2026. SiteOne is stepping in as Integer Holdings Corp. (NYSE: ITGR) makes its grand exit, a move prompted by a significant acquisition by KKR & Co. Inc. (NYSE: KKR). KKR’s...

Continue Reading
Halfday Iced Tea Shakes Up U.S. Retail Scene

Updated Category News Views 142

Halfday's Meteoric Rise in the U.S. Market Sometimes, you pick up a can of iced tea, and it just changes the game. That’s exactly what Halfday is doing, stepping on the accelerator and leaving traditional iced tea brands in the dust. With their latest announcement, they've snagged the title of the fastest-growing modern tea brand in U.S. multi-outlet retail. It's the...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 222

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading
Nord Anglia Schools Shine with 13 Tes Awards Nominations

Updated Category News Views 154

Nord Anglia's Moment of Glory at Tes Awards You think you know the big players in the educational game? Well, guess again. Nord Anglia's come out swinging with a whopping 13 finalist nominations at the 2026 Tes Awards for International Schools. It ain't easy making waves in the education sector, but these folks are showing they've got what it takes to turn heads, not just...

Continue Reading
Trades Workforce Shortage Costs Wallop U.S. Economy

Updated Category News Views 113

The Forgotten Backbone of America Don't sleep on this: America's got itself a trade worker crisis, and it's not just a numerical hiccup. We’re down nearly 1.9 million skilled trades workers, and that's a gut punch to the economy—a hefty $1.2 billion a day in GDP loss. These are the folks who keep the wheels greased, the lights on, and the goods flowing. Without them,...

Continue Reading

Top 5 Most Recently Viewed Articles

Market Insights: S&P 500 Forecasted Decline and Job Growth Impact

Updated Category News Views 107

Market Insights on Economic Factors Impacting S&P 500 Recent reports have revealed that the job market in the United States is displaying significant strength. According to recent statistics, there was an addition of 256,000 jobs, which paints a picture of a robust economy. However, this strong job growth can bring mixed signals for investors regarding the stock market,...

Continue Reading
Safety Tech in Fleets: Drivers Embrace Its Role

Updated Category News Views 65

Drivers Warming Up to Fleet Safety Tech Seems like most fleet drivers these days are eyeing safety tech through a fresher lens. Gone are the days when grumbling about privacy was the anthem of the disgruntled. The latest Linxup survey claims a whopping 77% of commercial fleet pros have hopped onto the safety train, happily trading privacy qualms for the perks of solid...

Continue Reading
Celebrating 50 Years of Excellence at Amerijet Airlines

Updated Category News Views 200

Amerijet International Airlines: A Milestone Celebration Amerijet International Airlines proudly celebrates its 50th anniversary this year, marking five decades of dedication to air cargo services that connect diverse regions. Founded by David Bassett in 1974, the airline began its journey as a small Part 135 air-taxi operator, operating a single leased aircraft. Over the...

Continue Reading
Petit Pot Wins $100K Prize at 2024 Real California Milk Event

Updated Category News Views 195

Petit Pot Celebrates a Momentous Achievement in Dairy Innovation In an exciting showcase of dairy innovation, Petit Pot has emerged as the grand prize winner of the 2024 Real California Milk (RCM) Excelerator competition. This prestigious award highlights the company's commitment to producing high-quality dairy-based desserts and its remarkable sales achievements in a...

Continue Reading
Exploring the Affordability and Safety Debate in Autos

Updated Category News Views 295

Affordability Angst, and a Scapegoat Nobody Asked For Echoes of old policy fights come roaring back here—every time car prices spike, somebody points at safety rules like they’re the boogeyman under the bed (and, yeah, it kinda ticks me off). Lawmakers have been poking at features like Auto Emergency Braking, and the broader affordability debate has gotten tangled up...

Continue Reading